Call us 24/7

Clinical trials

Filters

38 Clinical Trials

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

A Phase 2, multi-center, open-label, two-stage study to assess the safety, tolerability, and efficacy of XERMELO in combination with first-line (1L) therapy (cisplatin [cis] plus gemcitabine [gem]) in patients with unresectable, locally advanced, recurrent or metastatic biliary tract cancer (intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer), who are naïve to tumor-directed therapy in the locally advanced or metastatic setting, and for which treatment with 1L therapy (defined as a combination of cis/gem) is planned.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

The purpose of this study is to assess the efficacy and safety of pembrolizumab vsersus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in the treatment of adults who have high-risk early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This randomized, phase II/III trial studies how well standard-of-care therapy with stereotactic radiosurgery and/or surgery works and compares it to standard-of-care therapy alone in treating patients with breast cancer that has spread to one or two locations in the body (limited metastatic) that are previously untreated.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

The purpose of this study is to determine if the study drug talazoparib (also called BMN 673) is safe when given as a breast cancer treatment and to evaluate how cancer responds to it.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is an open-label, three-part, multiple-dose study to evaluate safety, tolerability and efficacy of U3-1402 in patients with HER3-positive metastatic breast cancer.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

The purpose of this study is to test study treatments that combine an investigational drug (tucatinib, which is also known as ONT-380) (the “study drug”) with two approved drugs (capecitabine and trastuzumab) in participants with advanced breast cancer to find out what effects, good or bad, it may have on the participants and their disease.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

A phase 3 multi-center, randomized, open-label trial to evaluate the efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR-positive, HER2-negative early breast cancer.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy X-rays to kill tumor cells. It is not yet known whether comprehensive radiation therapy is more effective than standard radiation therapy in treating patients with breast cancer.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

The goal of this clinical research study is to learn if adding panitumumab to the combination of carboplatin and paclitaxel can help to control inflammatory breast cancer when given before other standard chemotherapy and surgery. The safety of these drug combinations will also be studied.